Kornimate/medical-research-clean huggingface dataset:
prevalence and risk factors of women mental health disorders

Conditions: Psychiatric Problem; Wolman Disease

Summary: perinatal major depressive disorder affects 20% of women, while perinatal anxiety affects 10% of women. although pharmacological treatment has shown effectiveness, many pregnant women are concerned about potential adverse effects on the fetus, maternal-infant bonding, and child development.. on the other hand, depressive disorder in women mainly occurs during the first year after childbirth. it takes many forms according to the onset, severity, and duration of the symptoms including; postpartum blues (ppb), postpartum depression (ppd), and postpartum psychosis (ppp). lack of access to mental health services during the perinatal period is a significant public health concern that may worse outcome. so, we aimed to study prevalence of women mental health in assiut governorate and evaluate possible risk factor for it


Eligibility criteria:
inclusion criteria: * age 18 years -50 years. * no previous history of psychiatric, neurological or medical disease exclusion criteria: * intelligence equation less than 80 * have history of psychiatric, neurological or medical disease

Keywords: women mental health
positive airway pressure versus breathing exercises with load inspiratory in patients undergoing bariatric surgery

Conditions: Inadequate or Impaired Respiratory Function

Summary: obesity, due to excess fat in the thoracoabdominal region, can promote changes in respiratory function and lung function, leading to reduction in lung volume and capacity. such dysfunctions are worsen after bariatric surgery to be associated with factors inherent to this procedure. the objective of this study was to evaluate and compare the effects of the application of bilevel positive airway pressure and exercises with inspiratory pressure with linear load in thoracoabdominal mobility, pulmonary function, inspiratory muscle strength, respiratory muscle strength and prevalence of pulmonary complications after bariatric surgery.

this is a clinical trial, randomized, blinded, in which 60 volunteers, after evaluation preoperatively, consisting of: cirtometry to measure thoracoabdominal mobility, spirometry for measures of lung function, nasal inspiratory pressure to inspiratory muscle strength and endurance incremental test for evaluation of respiratory muscle strength, were randomized and allocated into three groups, with 20 volunteers each. the interventions were performed in the immediate postoperative period and the first day after surgery. the first group, called the control group received care by conventional respiratory physiotherapy (crp), consisting of breathing exercises, incentive spirometer and ambulation. the second group, called positive pressure group received two-level positive airway pressure for one hour, addition of crp. the third group, called load inspiratory group held exercises with inspiratory pressure with linear load, linked also to the crp. treatments were applied twice in the immediate postoperative period and shortly after returning to the ward and after 4 hours of the initial treatment and three times a day on the first day after surgery. on discharge, the second day after surgery, the volunteers performed chest x-ray and underwent the same evaluations performed preoperatively.

Eligibility criteria:
inclusion criteria: * submitted to roux-en-y type gastric bypass by laparotomy * normal preoperative pulmonary function and chest x-ray exclusion criteria: * hemodynamic instability * hospital stay longer than three days * presence of postoperative complications * smoking * respiratory chronic diseases

Keywords: gastroplasty, breathing exercices, positive pressure
gi symptoms in infants fed gmf or cmf

Conditions: Gastrointestinal Diseases; Infant Nutrition Disorders

Summary: the aim of this study was to assess common gastrointestinal symptoms in healthy brazilian infants receiving goat milk-based infant formula (gmf) compared to cow's milk-based infant formula (cmf) during a 24 week intervention.

anecdotal evidence shows that the use of goat milk-based infant formula decreases discomfort of infants with cow's milk related symptoms. in this double-blind, randomized controlled trial, gastrointestinal comfort in infants fed goat milk-based infant formula (gmf) or cow's milk-based infant formula (cmf) was studied. fifty-six healthy infants aged 3-12 months were followed for 24 weeks. stool consistency, regurgitation frequency and crying duration were measured weekly using an adapted version of the cow's milk-related symptom score (comiss®) where only the items for these scores were used. blood hemoglobin levels were measured at the start and at the end of the intervention.

Eligibility criteria:
inclusion criteria: * gestational age 37-42 weeks * 3-12 months old at enrollment * should have consumed cow's milk-based products during the 48 hours prior to the baseline visit to exclude cow's milk allergic infants exclusion criteria: * metabolic or chronic disease or congenital malformation, serious concurrent illness that would interfere with study treatment, (i.e. sepsis, pneumonia with respiratory failure, cardiac failure) * infant's parent(s) or primary caregiver(s) diagnosed with major depression * infant's weight for length at baseline \>\|3\| z-score indexes according to who criteria * infants enrolled in another interventional clinical research study * infants diagnosed with cow's milk allergies

Keywords: goat milk-based infant formula infant formula gastrointestinal comfort infant nutrition
prostate guided biopsy study evaluating the diagnostic performance of prostate histoscanning

Conditions: Prostate Cancer

Summary: the primary objective of the phstt-01 trial is to determine if prostate histoscanning (hs) analysis can be used to improve the detection of clinically significant prostate cancer (pca), and potentially reduce the burden and number of biopsies in routine clinical practice. prostate hs is an ultrasound-based tissue characterization technology specifically developed to detect, visualize, and locate tissue suspected of harboring pca. these suspicious tissues are displayed as red areas on an imaging monitor. recently a new biopsy guidance tool has been developed that uses the results of the prostate hs analysis. the subjects that will participate in this study are all scheduled for a first biopsy of the prostate. they will initially be imaged using transrectal ultrasound (trus) to obtain data for prostate hs analysis. the results of hs analysis will be used later in the procedure. subjects will then undergo a routine systematic 10- to 12-core biopsy procedure using trus. this will be followed by a trus-guided biopsy that uses the result of prostate hs analysis and new biopsy guidance tool.

phstt-01 is a multi-center, prospective clinical trial to evaluate the diagnostic performance of prostate histoscanning (hs) analysis in men at risk of pca that have been scheduled for a first prostate biopsy. the purpose of this study is to determine if prostate hs analysis can improve the detection of clinically significant pca, and potentially reduce the burden and number of biopsies in routine clinical practice. subjects are men with serum total prostate-specific antigen (pca) \<= 20ng/ml (\<= 10ng/ml if taking the 5-alpha reductase inhibitor). in a single visit, subjects will first be imaged with trus for the purpose of generating data for prostate hs analysis. the results of hs analysis will be used later in the procedure. subjects will then undergo two consecutive biopsy procedures. first, using trus, a systematic 10- to 12-core biopsy procedure will be performed. in turn, prostate hs data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. depending on the number of suspicious areas identified by prostate hs, the number of cores will be zero to a maximum of 6 cores.

Eligibility criteria:
inclusion criteria: * men at risk of pca scheduled for first biopsy with serum total psa ≤ 20 ng/ml (≤ 10 ng/ml if taking 5-alpha reductase inhibitors) from maximally 3 months ago * signed informed consent exclusion criteria: * previous prostate biopsy * confirmed pca * psa \> 20 ng/ml (or \> 10 ng/ml if taking 5-alpha reductase inhibitors) * active urinary tract infection * presence/history of any confirmed cancer * recent prostatic surgery (past 6 months) * history of pelvic radiotherapy

Keywords: histoscanning trus prostate cancer biopsy guidance
augmenting exposure therapy for social anxiety with transcranial direct current stimulation

Conditions: Social Anxiety

Summary: this study will examine whether transcranial direct current stimulation (tdcs) can be used to improve outcomes from exposure therapy for social anxiety disorder, and facilitate extinction of fear responding toward individuals outside one's own ethnic group (i.e., ethnic out-group members).

although exposure therapy is among the most powerful treatment techniques for social anxiety, many individuals do not achieve full remission. furthermore, some research suggests that fear responding toward ethnic out-group members may be more resistant to extinction. enhancing activation of the mpfc during exposure therapy may improve overall response to treatment, and also facilitate extinction of fear toward ethic out-groups. researchers have found that greater mpfc activation during exposure therapy is associated with better outcomes, and that transcranial direct current stimulation (tdcs) can be used enhance learning and cognition with no known serious adverse effects. this study will therefore examine whether active/anodal (versus sham) tdcs targeting the mpfc (a) enhances overall reductions in social anxiety symptoms, and (b) facilitates extinction of fear responding toward ethnic/racial out-groups for both latino and caucasian/non-latino participants. participants will receive either active/anodal tdcs or sham tdcs during a brief exposure therapy intervention involving public speaking in a virtual reality (vr) environment. the public speaking audience in the vr environment will alternate between audiences that are either matched or unmatched to the participant's ethnicity (in a randomly assigned order). participants' fear reactivity will be assessed with behavioral, physiological, and subjective measures at baseline, post-treatment, and follow-up.

Eligibility criteria:
inclusion criteria: * age 18 or older (adult) * enrolled in higher education (post-high school) * elevated public speaking anxiety as indicated by self-report questions * not currently receiving in exposure therapy for social anxiety exclusion criteria: * history of seizure or any other neurological diagnosis * has any metal in their skull (plates, steel sutures, etc.) * participant is currently taking anti-convulsant, sedative/hypnotic, or antipsychotic medications * participant is pregnant * participant has already participated in a prior tdcs/tacs study on the same day as study visit 1 (which will involve either placebo or active/anodal tdcs stimulation)

Keywords: social anxiety transcranial direct current stimulation exposure therapy
a randomized control study of anti-adhesion agent after colorectal surgery

Conditions: Adhesion

Summary: this project is to evaluate the difference of post-operation adhesion severity and adhesion area of patient received 4dryfield after colorectal surgery.

this proposal will investigate the effect of the newly anti-adhesive agent 4dryfield. stoma creation is common in complicated colorectal disease. hartman procedure (end colostomy) is used in patients advanced rectal cancer or severe diverticulitis. loop colostomy or ileostomy is used in patients need stool diversion for prevent leakage related infection. 4dryfield is a powder consisting of sterile hydrophilic microparticles, which is anufactured from highly purified potato starch in a complex process. a unique starch-based medical device is 4dryfield® ph (4dryfield; planttec medical gmbh, germany) as it is the only product proven to provide hemostasis and prevent the formation of adhesions. in rat model, the 4dryfield acheieve the significant adhesion prevention effectiveness. in gynecologic surgery, 4dryfield showed effective adhesion prevention as confirmed at second look laparoscopy. the gel is easilier to applied in the uneven surface of pelvic cavity and peristomy area than other manufacture. the indication of adhesion prevention is approved by tfda.

Eligibility criteria:
inclusion criteria: * patients undergoing colorectal resection and temporary stoma exclusion criteria: * - pregnancy, child, psychiatric disorder, behavior disorder, and prisoner. and those patients can't follow the protocol

Keywords: adhesion post-operation colorectal surgery
a study of ocrelizumab in participants with follicular non-hodgkin's lymphoma (nhl)

Conditions: Non-Hodgkin's Lymphoma

Summary: this study will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of ocrelizumab in participants with progressive follicular nhl.


Eligibility criteria:
inclusion criteria: * follicular nhl * documented history of response, or stable disease more than 6 months in duration, to a rituximab-containing regimen that was the last treatment before enrollment in the study * no evidence of hepatitis b or c exclusion criteria: * prior monoclonal antibody therapy other than rituximab, anti-cancer vaccine, or radioimmunotherapy for cancer * history of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies, or known sensitivity or allergy to murine products * major nondiagnostic surgery within 4 weeks of screening
oncological and functional outcomes of laparoscopic partial nephrectomy in renal cell carcinoma stages t1 versus t2a: prospective comparative study.

Conditions: Renal Cell Carcinoma

Summary: rcc represents around 3% of all cancers, with the highest incidence occurring in western countries . within the several rcc risk factors identified, smoking, obesity, and hypertension are most strongly associated with rcc . the eua guidelines recommend pn for patients with t1 tumors, as pn preserved kidney function better after surgery, thereby potentially lowering the risk of development of cardiovascular disorders as well as improving overall survival(os) for pn compared to rn, there is very limited evidence on the optimal surgical treatment for patients with larger renal masses (t2) . currently, the upper limit of pn indications remains undefined and is determined by an individual surgeon's expertise and preference. the degree of variability in the choice between pn and rn for a given tumor increases with tumor size. surgeons committed to nephron-sparing are likely to expand the indications of pn, while those concerned with increased morbidity and doubtful of the clinical relevance of a moderate decrease in renal function are likely to perform rn, regardless of tumor size .


Eligibility criteria:
inclusion criteria: * patients with localized rcc ≤ 10 cm in preoperative contrast enhanced imaging(t1 and t2a). exclusion criteria: * patients who had other tumors * benign tumors * clinically unfit * metastatic rcc * patients with clinical t2b or higher tumors, * tumors with maximum diameter \> 10cm
effectiveness of endonasal polymeric implant for chronic rhinosinusitis

Conditions: Rhinosinusitis Chronic

Summary: objective: the objective of this study is to evaluate a steroid-embedded terpolymers polymer implant of l-lactide and trimethynele carbonate (tcm) at the level of disease control in patients with eosinophilic and central compartment chronic rhinosinusitis (crs) after placement of the endonasal device, compared to a control group (placebo). the secondary objectives of this study are to assess comfort, perception of improvement and satisfaction, as well as adverse events. methods: a randomized controlled trial will be carried out, with a blinded participant, therapist and evaluator. patients over 18 years of age, with chronic rhinosinusitis (crs) who have already undergone endoscopic sinus surgery (cens), but who do not have the disease under control and, therefore, with an indication for a new cens, will be selected. participants will come from the otorhinolaryngology outpatient clinic of the academic and public service of the university of são paulo - usp. eligible patients will receive either the terpolymers l-lactide and trimethynele carbonate (tcm) polymer implant placement or the placebo polymer. the primary outcome will be the control of the symptoms of chronic uncontrolled rhinosinusitis that will be evaluated through the nose questionnaire, a nasal endoscopic evaluation based on the lund-kennedy criteria and the snot-22 questionnaire. the sample size calculation was performed based on a difference between the intervention and placebo groups of 30% for cases that achieved disease control, resulting in a sample of 36 participants (18 in each group). data will be analyzed using mixed linear models.


Eligibility criteria:
inclusion criteria: - patients with chronic rhinosinusitis undergoing endoscopic sinus surgery, but who do not have the disease under control. the uncontrolled disease and its respective classification regarding the degree of the disease will be carried out through 3 assessments: 1) nose obstruction symptom evaluation questionnaire (nose) validated version in portuguese; 2) nasal endoscopic evaluation; and, 3) sino nasal outcome test questionnaire (snot-22). through the nose questionnaire, the patient's disease will be classified as "controlled", "partially controlled" or "uncontrolled (uncontrolled)". any variation in the endoscopic evaluation score based on the lund-kennedy criteria will be considered an alteration. and for the snot-22 questionnaire, changes will be considered when the total score varies by at least 11 points. patients who present these 3 alterations will be considered to have the 'uncontrolled disease' and, therefore, will be eligible for the study. exclusion criteria: * patients with malformations, trauma and/or tumors in the nasal and paranasal sinuses will be excluded; * patients with a history of recent nasal surgery up to 6 months previously, with glaucoma and cataracts.
anterior pituitary hormone replacement in traumatic brain injury

Conditions: Growth Hormone Deficiency; Traumatic Brain Injury

Summary: fifteen to twenty percent of adults who suffer a traumatic brain injury (tbi) that requires hospitalization and rehabilitation have been found to have growth hormone (gh) deficiency by gh stimulation testing. moreover, abnormalities have also been established for the cortisol and thyroid axis. the hypothesis of this proposal is that hormone replacement in tbi patients with documented abnormalities in the gh, thyroid, or cortisol axis will improve muscle function, body composition, aerobic capacity (gh) and tests of neuropsychologic function (gh, thyroid, cortisol).

this protocol is designed to screen and detect evidence of pituitary hormone deficiency in adults following traumatic brain injury. growth hormone deficiency will be replaced for a period of one year. subject will not be screened until at least one year following brain injury to allow for natural recovery of hormone function.

Eligibility criteria:
inclusion criteria: * patients aged 21 and older. * documented moderate to severe traumatic brain injury at least one year post injury. exclusion criteria: * the only absolute exclusionary medication will be an anticoagulant (coumadin) because of the risk of bleeding during the possible muscle biopsy procedure and daily injections of rhgh in the gh arm of the study. * any subject with a history of hepatitis or a 3-fold elevation of liver function tests (alk phos, alanine aminotransferase (alt), aspartate aminotransferase (ast)). we are uncertain of the effects of hormone replacement such as rhgh on the liver, so we will exclude any subjects with hepatitis. this exclusion applies only to subjects who would be enrolled in the gh arm of the study. * subjects who are deficient in cortisol or thyroid at screening will be excluded until hormone abnormalities have been corrected. * subjects with chronic pain who are being managed with narcotics will be excluded as the effects of central nervous system depressants may interfere with study test results.

Keywords: tbi traumatic brain injury growth hormone deficiency anterior pituitary hormone recombinant human growth hormone genotropin
performance evaluation of the navicam sb capsule endoscope system for the diagnosis of small bowel diseases

Conditions: Small Bowel Disease

Summary: this study uses a comparative method to evaluate the performance of the navicam sb capsule endoscope system in comparison to the pillcam sb3 capsule system for the diagnosis of small bowel diseases.

this study adopts a prospective and self-controlled design. the subjects are adult patients (≥18 years old) who have symptoms of small bowel disease or suspected gi bleeding; subjects swallow two types of sb capsules approximately 40 minutes apart in a randomized order. during the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time. this study adopts a method of independent image reading in the participating centers. two physicians of digestive endoscopy respectively review the images captured by the experimental capsule and the control capsule for normal versus abnormal findings, type of findings and categorization (lesions, polyps, bleeding, etc.), capsule transit time, reading time, and image quality.

Eligibility criteria:
inclusion criteria: 1. adult patients (≥18 years old) who have symptoms of small bowel disease or suspected gi bleeding; 2. those need capsule endoscopy because the recurring gi symptoms cannot be explained by other imaging methods; 3. those can understand and accept this study protocol and voluntarily sign an informed consent. exclusion criteria: 1. patient is expected to undergo mri examination within 7 days after ingestion of the capsule; 2. patient with known gastrointestinal motility disorders; 3. patient with known or suspected gastrointestinal obstruction, stenosis or fistula; 4. patient with known or suspected delayed gastric emptying; 5. patient suffers from any condition, such as swallowing problems, which precludes compliance with study and/or device instructions; 6. patient has any allergy or other known contraindication or intolerance to the medications used in the study; 7. patient has any condition, which precludes compliance with study and/or device instructions; 8. women who are either pregnant or nursing at the time of screening; 9. concurrent participation in another clinical trial using any investigational drug or device; 10. patient suffers from a life-threatening condition; 11. patients with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters; 12. patients with pace-maker or implantable cardioverter other implantable electronic medical device; 13. patient with an easily magnetized metal part; 14. patient requires endoscopic placement of the capsule; 15. others considered by the investigator not suitable for this study.